Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases (Q34096275)

31 July 2017

1 reference

title

Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases (English)

1 reference

31 July 2017

0 references

Illei GG

1

1 reference

PubMed ID

11102777

31 July 2017

Lipsky PE

series ordinal

2

1 reference

31 July 2017

1 December 2000

1 reference

Current Opinion in Immunology

31 July 2017

1 reference

31 July 2017

12

1 reference

31 July 2017

712-718

1 reference

31 July 2017

6

1 reference

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900167-9

7 January 2021

10.1016/S0952-7915(00)00167-9

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11102777